Newsbenzinga
Jazz Pharmaceuticals' New Cancer Drug Drives $1.3 Billion Opportunity, Says Analyst
· Published
Article summary
Jazz Pharma (JAZZ) revenue growth driven by Ziihera adoption as 1L treatment for HER2+ GEA, says BofA analyst.
An excerpt from the original article.
Comments —
Loading comments…